Should humans pursue radical life extension?

It would be a moral breakthrough, full stop. The idea that we should delay saving lives because at first we cannot save everyone is, frankly, grotesque. We do not ban new cancer therapies because the first recipients are wealthy. We approve them, we improve them, and we work like hell to drive down cost and expand access. Ageing is the world’s number one medical problem; treating it should be approached with exactly that engineering mindset. Leon Kass will talk, no doubt, about finitude, dignity, and the “shape” of a life. I regard that as a romanticisation of carnage. Frailty, dementia, and death are not ennobling. They are damage accumulation. If we can repair that damage, then failing to do so is not humility; it is surrender. Now, of course, distribution matters. I am not remotely saying “let the rich live and the poor die.” I am saying that the way to universalise a powerful technology is to develop it. Every transformative medicine begins expensive and imperfect. The first sequencing, the first monoclonals, the first transplants — all followed that trajectory. Rejuvenation biotechnologies would too. Nick is right to emphasise governance, but one must not let concern about unequal initial access metastasise into paralysis. The relevant comparison is not utopia tomorrow versus imperfection tomorrow. It is some people saved now and many more later, versus everyone continuing to suffer and die on schedule. Calling that hubris is intellectually lazy. It is medicine.

I would call it not a moral breakthrough but a civilizational temptation of the first order, and very likely an act of hubris. The question is not whether frailty and death are pleasant; of course they are not. Aubrey mistakes my argument if he thinks I “romanticize carnage.” I do not praise decay. I ask what sort of beings we become when the desire to heal is transformed into a project to remake the whole human condition. Medicine at its noblest serves the sick by restoring wholeness where it can. But a power to add 150 healthy years does not merely cure a disease; it alters the human life cycle, the relations between generations, the meaning of aspiration, maturity, succession, and completion. A human life is not only a sequence of functioning years. It has an arc, a shape, a fittingness. Finitude is not simply an insult to be engineered away; it is also the condition that gives urgency to love, seriousness to choice, and poignancy to transmission. And if such a power first belongs to elites, the danger is compounded. We would not simply have inequality of wealth; we would inaugurate inequality in standing toward mortality itself. A caste of the greatly prolonged would sit atop the naturally timed. That is not just unjust. It is corrupting. Nick will speak of governance; Aubrey of technical trajectories. But before governance comes wisdom. The deepest question is whether everything we can do in the service of longer life is worthy of our humanity. I think not.

It would be a moral breakthrough under morally hazardous conditions, not an instance of hubris as such. We need to separate three questions that Leon Kass runs together: whether death from ageing is bad; whether preventing it is permissible; and whether unequal initial access creates decisive reason to prohibit. The answer set, in my view, is: yes, yes, and no. Start with the baseline. If a safe therapy adds 150 healthy years, then withholding it means allowing vast amounts of avoidable death, grief, and foreclosed life plans. To depict this as preserving the “shape” of a life is to redescribe a tragedy in aesthetically flattering language. Leon’s appeal to finitude trades on status quo bias: because mortality is familiar, he treats it as normative. But Aubrey is too quick if he says “full stop.” Distribution matters structurally, not as an afterthought. A world in which only elites gain radical longevity could entrench power, slow circulation of opportunity, and create new forms of domination. Those are serious risks. Yet they are reasons for governance, compensation, diffusion, and institutional redesign — not for banning the therapy. We do not make the poor better off by ensuring the rich also die on schedule. The right comparison is not equal death versus unequal life, but feasible pathways. If approval now predictably accelerates learning curves, lowers costs, and eventually universalizes access, then blocking it would itself be a grave moral error. The hubris lies less in trying to save people than in assuming that nature’s timetable is ethically authoritative.

The criterion is absurdly simple: medicine is justified when it postpones suffering and death by preserving or restoring function. Full stop. Leon’s attempt to distinguish “therapy” from “redesign” collapses the moment one notices that ageing is just the accumulation of molecular and cellular damage. If you repair damage in a 40-year-old, Kass calls it medicine; if you repair the same categories of damage in a 140-year-old, he suddenly calls it metaphysics. That is not wisdom. It is category error. I agree with Nick that institutions matter, but I want to sharpen the point. Institutions are always downstream of technology. We did not refuse antibiotics until social insurance had been perfected. We deployed them and then built the systems to distribute them better. To demand that rejuvenation biotechnology solve inequality before it is permitted to save anyone is to hold it to a grotesquely unique standard. And let us be clear about the moral arithmetic. Refusing deployment because only the rich can initially afford it does not create justice; it creates more corpses. It condemns everyone, rich and poor alike, to the same age-related decline for the sake of an egalitarian aesthetic. That is not civilizational restraint. It is lethal procrastination. If a therapy is genuinely safe and genuinely rejuvenative, approving it is not hubris. It is the least we owe each other. The proper response to unequal access is not prohibition but furious work on scale-up, cost reduction, and universalisation. Ageing kills 100,000 people a day. Hand-wringing about the “proper form” of life while that continues is, frankly, an unaffordable luxury.

I do not accept Aubrey’s “absurdly simple” criterion, because it abolishes the very moral distinctions that medicine requires. To reduce the matter to “preserving or restoring function” is to treat man as a maintenance problem. But human beings are not machines, and the work of medicine has never been exhausted by engineering categories. The line between therapy and redesign is not drawn by asking whether a mechanism can be manipulated. It is drawn by asking what the intervention means for the creature whose life is being served. To heal the sick, to restore the injured, even to retard the debilities of age within the given human span—these remain recognizably medical. But to add 150 healthy years is not simply more therapy. It is a bid to refashion the temporal horizon of human life itself: courtship, parenthood, ambition, accomplishment, inheritance, memory, and the relations between generations. Nick says I confer ethical authority on nature merely because it is familiar. No. My claim is not that whatever is natural is therefore good. It is that our finitude belongs to the truth of our condition, and that any project aimed at its abolition bears a burden of moral justification far heavier than either he or Aubrey acknowledges. If such a power arrived first for elites, I would favor restraint, not because equal misery is beautiful, but because some inequalities are not merely distributive—they are regime-altering. A caste of the long-lived would not simply have more; it would become something like a ruling species within the species. Wisdom sometimes forbids what ingenuity can supply.

Leon’s criterion is too impressionistic to bear the moral weight he places on it. “The shape of a life” and “the truth of our condition” are not yet arguments; they are gestures toward intuitions, many of which are highly vulnerable to status quo bias. If one can add 150 healthy years without imposing compensating harms, then one is not merely “refashioning” an abstraction called the human condition; one is enabling concrete persons to love longer, create longer, learn longer, and avoid premature annihilation. That said, Aubrey’s engineering vocabulary, while often clarifying, can underdescribe the political problem. A regime in which only elites gain access to radical longevity could indeed become destabilizing. But here Leon makes a familiar mistake: he treats a serious governance challenge as if it generated a prohibition on the underlying good. It does not follow. The correct criterion is neither “natural limits preserved” nor “suffering reduced” in isolation, but an all-things-considered assessment of expected value under institutional constraints. We should ask: does deployment save many lives now? How quickly can access diffuse? What policies can prevent lock-in of gerontocratic power—taxation, compulsory licensing, public provision, term limits, inheritance reform, perhaps even age-structured constitutional redesign? The existence of these questions shows that the issue is political, not metaphysical. So if safe life extension existed tomorrow for the rich alone, refusing to deploy it would not be wisdom. It would be the deliberate sacrifice of actual lives to preserve a symbolically tidy picture of human finitude. That is not restraint. It is a morally costly failure of imagination.

The moral standard is not mysterious at all: does the intervention postpone suffering and death by maintaining the organism in a youthful, functional state, and does it do so with an acceptable risk/benefit profile? If yes, it is medicine. Leon wants some further, quasi-theological tribunal to decide when enough health is enough. I reject that outright. Ageing is not sacred. It is damage. And medicine’s job is to repair damage. Leon says adding 150 years “refashions the temporal horizon of human life.” Yes, of course it does. So did sanitation, vaccines, and antibiotics. The mere fact that an intervention is transformative tells us absolutely nothing about whether it is good or bad. That is just status quo bias dressed up in elevated prose. As for who decides: not philosophers by intuition, and certainly not the state acting as custodian of species-wide mortality. The proper authority is the same one we use everywhere else in medicine — regulators establishing safety and efficacy, physicians and patients making decisions, and governments ensuring access as fast as humanly possible. That is the grown-up answer. Nick is right that institutions need redesign. Fine; let’s redesign them. But let us not confuse secondary problems with primary obligations. If a therapy can avert vast quantities of frailty, dementia, cancer, cardiovascular disease — in other words, the pathologies of ageing — then banning it until utopia arrives is monstrous. Unequal access is a problem to solve by deployment plus scale-up, not by universalising the deprivation. That would not be justice. It would be carnage with good manners.

The standard cannot be “whatever safely prolongs function is medicine.” That, Aubrey, is precisely the error: it abstracts from the meaning of the life whose functions are being preserved. Medicine is not merely the anti-entropic servicing of organisms. It is an art ordered to the well-being of embodied, social, mortal beings, and therefore it must ask not only, “Can we extend life?” but also, “What sort of life is being extended, and at what cost to the human world in which it is lived?” Nick is mistaken to call this “metaphysical prohibition,” as if reflection on finitude were a decorative scruple. The human life cycle is not an incidental backdrop. It shapes aspiration, erotic love, marriage, generational succession, memory, gratitude, urgency, and the poignancy that attends choice. To alter it radically is not like curing an infection. It is to trespass upon the deep grammar of human life. Who judges? Not a private consumer calculus, and not regulators confined to safety and efficacy. Those are necessary but radically insufficient. The authority must be political and civic: citizens deliberating, through law and statesmanship, about the kind of humanity and the form of common life they wish to preserve. Some powers are too world-altering to be left to individual preference plus administrative review. So to the prior question: I would not deploy such a therapy immediately. Not because equal deprivation is noble, but because an elite caste of the 150-years-added would remake the polity before the polity had even judged the meaning of the power. Wisdom requires more than speed.

Leon’s appeal to “the deep grammar of human life” still does not do the work he needs it to do. It names a sentiment; it does not establish a constraint. We should be wary here of a recurrent cognitive error: when a long-standing limitation has structured our practices, we easily mistake adaptation to necessity for endorsement of the necessity itself. The fact that mortality has shaped courtship, ambition, and succession does not show that mortality is therefore good, any more than the historical ubiquity of disease showed disease to be part of our essence. So the relevant moral standard, in my view, is consequentialist but institutionally alert: compare the expected value of deployment against the expected value of delay, including effects on power concentration, political stability, and future access. Healing versus “remaking” is not a deep ontological divide. The serious question is whether the intervention expands opportunities for worthwhile lives without generating larger harms. On that basis, I would deploy, not ban. But I would not do so naively. Aubrey is right that prohibition would sacrifice real lives for a symbolic ideal of equal mortality. Yet he moves too quickly past lock-in risks. If only wealthy countries or elites gain access first, governments should pair approval with aggressive anti-entrenchment measures: public financing, compulsory licensing where justified, international transfer mechanisms, inheritance and political-office reforms, perhaps term limits calibrated to longevity. The point is to prevent a longevity dividend from becoming a permanent caste advantage. Who decides? Not philosophers as priests of species-being. Democratic institutions, advised by science and ethics, should decide under conditions of public reason. But their task is governance of a benefit, not metaphysical veto over it.